在动脉样硬化中通过DNA甲基化使单碳酸盐运输体MCT3失活
Shoukang Zhu1, Pascal J Goldschmidt-Clermont, Chunming Dong
1Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Circulation
|August 24, 2005
概括
DNA甲基化抑制了光滑肌细胞中的单碳酸盐运输体3 (MCT3) 表达,从而损害了乳酸运输. 这种表观遗传调节与SMC的扩散和动脉样硬化发展有关.
科学领域:
- 细胞生物学 细胞生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 心血管研究的心血管研究.
背景情况:
- 单碳酸盐运输体 (MCTs) 促进乳酸运输,这对细胞能量代谢至关重要.
- 在光滑肌细胞 (SMC) 中调节MCT的机制尚不清楚.
- 乳酸运输与诸如动脉样硬化等心血管疾病有关.
研究的目的:
- 研究DNA甲基化对SMCs中MCT表达和功能的影响.
- 确定MCT在SMC表型和动脉样硬化中的作用.
- 在SMC中阐明单碳酸盐运输的表观遗传调节.
主要方法:
- 实时RT-PCR,Western blotting和免疫组织化学用于MCT表达分析.
- 双硫酸盐测序用于评估SMC中的DNA甲基化模式.
- 对焦显微镜用于乳酸运输可视化和功能测试.
主要成果:
- 在繁殖的SMC中观察到MCT3的下调和乳酸运输的减少.
- 穿越数和动脉硬性病变进展与MCT3促进剂甲基化相关.
- 脱甲基化治疗恢复了MCT3表达和乳酸运输的正常化.
- MCT3的淘汰促进了SMC的扩散.
结论:
- DNA甲基化在表观遗传上调节了SMC中的MCT3表达.
- 通过甲基化抑制MCT3表达会损害乳酸运输,可能导致SMC的扩散.
- 这种机制可能有助于动脉样硬化的发病.
相关概念视频
Epigenetic Regulation
34.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.4K
Abnormal Proliferation
5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Epigenetic Regulation
4.2K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
4.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets
88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
Atherosclerosis III: Management
593
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
593


